期刊
PHARMACOGENOMICS
卷 17, 期 3, 页码 297-307出版社
FUTURE MEDICINE LTD
DOI: 10.2217/pgs.15.174
关键词
MAPK; mutation; p85; PI3K; PIK3R1; targeted therapy
资金
- NCI NIH HHS [R01 CA123219, P50 CA083639] Funding Source: Medline
The regulatory subunit of PI3K, p85 alpha (encoded by PIK3R1), binds, stabilizes and inhibits the PI3K p110 catalytic subunit. Functional characterization of PIK3R1 mutations has identified not only hypomorphs with reduced inhibition of p110, but also hypomorphs and dominant negative mutants that disrupt a novel regulatory role of p85 alpha on PTEN or neomorphs that activate unexpected signaling pathways. The diverse phenotypic spectrum of these PIK3R1 driver mutations underscores the need for different treatment strategies targeting tumors harboring these mutations. This article describes the functional consequences of the spectrum of PIK3R1 driver mutations and therapeutic liabilities they may engender.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据